BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2022 5:53:38 AM | Browse: 299 | Download: 591
 |
Received |
|
2022-03-11 14:44 |
|
Peer-Review Started |
|
2022-03-11 14:46 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-18 00:29 |
|
Revised |
|
2022-04-19 09:11 |
|
Second Decision |
|
2022-06-10 03:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-06-17 22:32 |
|
Articles in Press |
|
2022-06-17 22:32 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-28 01:01 |
|
Typeset the Manuscript |
|
2022-07-05 13:26 |
|
Publish the Manuscript Online |
|
2022-07-11 05:53 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Editorial |
| Article Title |
Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Awadhesh Kumar Singh and Ritu Singh |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Awadhesh Kumar Singh, MBBS, MD, Consultant Physician-Scientist, Intermediate Editor, Senior Postdoctoral Fellow, Senior Researcher, Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, 133A, Lenin Sarani, Kolkata 700013, West Bengal, India. draksingh_2001@yahoo.com |
| Key Words |
Renin-angiotensin system blockers; SGLT-2 inhibitors; Mineralocorticoid receptor antagonist; Diabetic kidney disease; Chronic kidney disease; Renal outcomes; Cardiovascular outcomes |
| Core Tip |
Angiotensin receptor blockers were the first drug class to show a conclusive benefit in preventing diabetic kidney disease (DKD) progression through two randomized trials IDNT and RENAAL in 2001. Several newer pharmacological agents have been tested in DKD in the past 20 years without much success. Notably, recently conducted renal outcome trials of SGLT-2 inhibitors in patients with DKD such as CREDENCE, DAPA-CKD, and EMPA-KIDNEY have shown significant improvement in disease progression. Similarly, recent trials of the non-steroidal mineralocorticoid receptor antagonist finerenone (FIDELIO-DKD and FIGARO-DKD) have shown significant improvement in both renal and cardiac endpoints in DKD. |
| Publish Date |
2022-07-11 05:53 |
| Citation |
Singh AK, Singh R. Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades! World J Diabetes 2022; 13(7): 471-481 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i7/471.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i7.471 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
